Gluten Intolerance Treatment Market Players:
- Takeda Pharmaceutical Company Limited
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- ActoBio Therapeutics, Inc.
- Precigen, Inc.
- Calypso Biotech BV
- ImmunogenX, Inc.
- Alvine Pharmaceuticals
- Dr. Falk Pharma GmbH
- ImmusanT, Inc.
- Zedira GmbH
- FunZyme BioTechnologies S.A.
- Amyra Biotech AG
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of gluten intolerance treatment is estimated at USD 1.05 billion.
The global gluten intolerance treatment market size was around USD 935.53 million in 2025 and is likely to expand at a CAGR of more than 13.8%, surpassing USD 3.41 billion revenue by 2035.
Europe is projected to command a 34% revenue share by 2035 in the gluten intolerance treatment market, attributed to increasing review of the broad spectrum of gluten-related disorders with focused clinical investigations, diagnostic criteria, and therapeutic approaches for different conditions causing gluten intolerance.
Key players in the market include IBM Corporation, HPE Symantec, CA Technologies, Mcafee Corporation, Oracle Corporation, Quest Software, NextLabs Inc., Veeam Software, Acronis International GmbH, Baffle Inc.
